In humans, hemodynamic changes observed within minutes after systemic administration of furosemide are often referred to as direct vasoactivity. However, these imme diate changes do not per se imply a direct vascular effect. We examined the genuine direct vascular effects of furosemide on the human forearm vascular bed and dorsal hand vein.
Background In humans, hemodynamic changes observed within minutes after systemic administration of furosemide are often referred to as direct vasoactivity. However, these imme diate changes do not per se imply a direct vascular effect. We examined the genuine direct vascular effects of furosemide on the human forearm vascular bed and dorsal hand vein.
Methods and Results Forearm blood flow in response to infusion of increasing dosages of furosemide into the brachial arte 17 was recorded by venous occlusion plethysmography. Local plasma concentrations of furosemide reached a maxi mum of 234±40 ju,g/mL during the highest infused dose but did not significantly affect the ratio of flow in the infused/non in fused arms. Venous distensibility of a dorsal hand vein was measured with a linear variable differential transformer. Dur ing precontraction with norepinephrine, five increasing dosages of furosemide (1 to 100 /¿g/min) were administered locally. Additional experiments using local administration of indomethacin or A/G-monomethyl-L-arginine (L-NMMA) were car ried out to determine whether effects were dependent on local prostaglandin or nitric oxide synthesis, respectively. Also, the effects of systemic administration of furosemide were exam ined. Local administration of furosemide led to a dose-depen dent venorelaxati on of 18 ± 6% at the first to 72±16% at the last dose. Indomethacin almost completely abolished furosemide-induced venorelaxation, whereas L-NMMA had no effect. Systemic administration of furosemide resulted in a time-dependent increase of hand vein distensibility, reaching 45±11% after 8 minutes.
Conclusions Furosemide does not exert any direct arte rial vasoactivity in the human forearm , even at supratherapeutic concentrations. In contrast, at concentrations esti mated to be in the therapeutic range, we observed a dose-dependent direct venodilator effect on the dorsal hand vein that appears to be mediated by local vascular prosta glandin synthesis. T he loop-active diuretic furosemide has been the standard treatment for heart failure for several decades. Apart from its primary diuretic action, furosem ide is also thought to have effects on the cardio vascular system. In heart failure, systemic administration of a loop-active diuretic has been reported to relieve the symptoms of pulmonary edema immediately, even be fo re diuresis sets in.!> 2 Although these effects are re ferred to as "direct" vascular effects, systemic adminis tration of a drug does not permit distinction between a direct action on the vascular wall versus changes induced by cardiovascular reflexes or regulatory systems.
It is well established that furosemide itself stimulates the release of renin, thereby increasing levels o f angio tensin IP '5 as well as of prostaglandins from the kidney.6 T h e effects on these two vasoactive hormonal systems have been associated with arterial vasoconstriction and venous vasodilation observed after systemic administra-tion of the drug.3* 4 Conversely, various in vitro experi ments indicate that furosemide, sometimes at rather high concentrations, does exert a direct vasodilator effect on isolated arterial7'8 and venous vessels.0 In the in vivo situation, this furosem ide-induced direct arterial vasodilation could be blunted by the vasoconstrictive effects of angiotensin II after systemic administration, and it is not clear whether the previously reported in vivo venodilation1'3'10 is the resuit o f a direct or indirect effect of furosemide on venous sm ooth muscle cells. Thus, up to now it is unknown whether furosemide-induced ef fects on systemic hemodynamics are the result of a direct or indirect action of the drug on the vasculature in vivo.
In the present study, we thoroughly investigated the genuine direct vascular effects o f furosemide on resis tance arteries in the forearm and on the dorsal hand vein of healthy subjects. T o this end, w e used the perfused forearm technique and the L V D T technique, respec tively. With these m ethods, interpretation of the results will not be confounded by direct effects on kidney or reflex effects secondary to changes in blood pressure or total plasma volume.
Methods

Subjects
Several protocols using two techniques were conducted for this study, all approved by the local ethics committee. Before participation, written informed consent was obtained from a total of 60 healthy volunteers. Participants were asked to refrain from drinking alcohol or caffeine-containing beverages for at least 24 hours before their studies. Salt intake was not restricted. None of the participants smoked or used any medication (including analgesics). All experiments were per formed in a single-blind fashion in a temperature-controlled laboratory (23°C to 24°C for the perfused forearm experiments and 28°C to 29°C for the venous distensibil ity measurements) with the subject in the supine position.
Demographic characteristics of the participants are summa rized in the Table. Arterial Vascular Activity Measurements Two protocols were conducted in a total of 22 subjects to assess the direct arterial vasoactivity of loop-active diuretics. First, we examined the direct arterial vasoactivity of furosemide and bumetanide and second, the effect of locally administered furosemide on norepinephrine-induced vasoconstriction. The perfused forearm technique was used for both protocols. For this technique, the left brachial artery was cannulated with a 2Q-gauge catheter (Angiocath, Deseret Medical, Becton Dick inson) after induction of local anesthesia (lidocaine 2%). This catheter was used for drug infusion (automatic syringe infusion pump, type STC-521, Terumo) and blood pressure monitoring (Hewlett Packard GmbH). At least 30 minutes after intra-arterial cannulation, baseline values of FBF were measured in both arms three times per minute by ECG-triggered venous occlusion plethysmography with mercury-in-Silastic strain gauges (Hokanson EC4, DE Hokanson) .11 To ensure that FBF recordings referred predominantly to the forearm skeletal muscle resistance arteries, the hand circulation was occluded during all FBF recordings by a wrist cuff inflated 100 mm Hg above the systolic pressure. 12 The upper arm collecting cuffs were simultaneously inflated to 45 to 50 mm Hg with a rapid cuff inflator . In all experiments, we also inserted a catheter into a deep ipsilateral forearm vein, During the last minute of each drug infusion period of 10 minutes, a venous blood sample was taken and drug concentrations were measured by high-performance liquid chromatography assay as previously described. 13 
Direct Arterial Vasoactivity of Loop-Active Diuretics
Dosages of furosemide were normalized to forearm volume (water displacement method). Total infusion rate was kept constant at 100 ¡jlL • min' 1 • 100 niL forearm volume"1. Furo semide was infused at 1, 3,10, 30, and 100 ¿xg • mill-1 * dL" 1 in 8 subjects. In another 6 subjects, furosemide was infused at 1000 ¡xg • min-1 ■ dL" 1 for 6 minutes. In 4 subjects, we admin istered bumetanide (0.025, 0.075, 0.25, 0.75, and 2.5 jug • min-1 • dL"1) instead of furosemide to perceive possible differ ences in vasoactivity between these two loop-active diuretics. 
Demographic Characteristics of the Study Groups
Effect of Furosemide on Norepinephrine-Induced Vasoconstriction
Animal data suggest that furosemide may exert an antivaso constrictor effect, because the drug did not directly dilate mesenteric resistance vessels but rather inhibited the vasocon strictor effect of norepinephrine and angiotensin II.14 To study this possible mechanism in humans, we measured the reduction of FBF in response to cumulative intra-arterial norepinephrine infusions in the absence and presence of local furosemide administration. In 4 subjects, norepinephrine was infused at 10, 30, and 100 ng • min' 1 • dL" 1 before and after local adminis tration of furosemide (10 /xg * min" 1 • dL-1 for 20 minutes, preceded by a 30-minute interval after the first norepinephrine dose-response curve). Previous experiments revealed that intrabrachial infusion of this dose of furosemide led to clinically relevant concentrations in the infused forearm.
Venous Vascular Activity Measurements
Four protocols were carried out to determine the venous vasoactivity of furosemide. The direct venous effect of locally administered furosemide was examined, after which involve ment of vascular prostaglandin and NO synthesis was assessed. Also, the venous effect of systemic administration of furo semide was examined. All protocols were conducted by the LVDT technique, in which venous distensibility of a dorsal hand vein was measured with the LVDT as described by Aellig15 and evaluated by Alradi and Carruthers,lfi A total of 5.1 experiments were performed in 28 young and 10 elderly subjects. Regression analysis established that there was no significant correlation between age and percentage venodila tion (/'=.18, P = NS), after which all data were pooled.
With the subject in the supine position in a temperaturecontrolled laboratory (28°C to 29°C), the arm under investiga tion was placed on a rigid support at an angle of 30° from the horizontal to allow complete emptying of the superficial hand veins. A sphygmomanometer cuff placed on the upper arm was then inflated to 45 mm Hg. A suitable large superficial vein with no apparent tributaries in the immediate area of exami nation was chosen, and a 23-gauge butterfly needle was in serted into the vein. The lightweight (0.2-g) probe of the LVDT was placed over the summit of the chosen vein 10 mm downstream from the tip of the needle. Under these condi tions, dorsal hand vein distensibility is maximal during venous occlusion. When the venous pressure remains constant at 45 mm Hg, changes in venous diameter are proportional to changes in venous Lone.
Owing to the low venous tone present under these condi tions,17 venodilator effects can be quantified only on veins that have been preconstricted. To examine furosemide-induced venodilation, we used continuous infusion of increasing con centrations of norepinephrine to precontract the veins. Infu sion of the norepinephrine concentration that achieved a precontraction of «=30% of maximal vein diameter was sus tained throughout the experiment. Previous experiments from our laboratory showed that this method has a good reproduc ibility: In 15 subjects, the coefficient of variation of the maximal vasoconstrictor response to norepinephrine (before and after an interval of 2 hours) was 9%. In addition, norepinephrine dose-response curves on different days did not differ signifi cantly from each other. Sustained infusion of norepinephrine alone resulted in a stable vasoconstrictor response (70±7% contraction after 10 minutes and 73 ± 6% after 60 minutes, n = 10), indicating the absence of tachyphylaxis to norepineph rine. During the experiment, blood pressure and heart rate were monitored every 5 minutes by a Dinamap 1846 SX attached to the contralateral arm.
Direct Venous Vasoactivity of Furosemide
In a total of 20 subjects, NaCl 0.9% (0.1 mL/min) was replaced by five increasing doses of furosemide (1, 3, 10, 30, and 100 /xg/min) at the same infusion rate for 10 minutes each. The cuff was deflated for 30 seconds every 5 minutes. At the end o f the experiment, saline was infused again, still with concomitant norepinephrine infusion.
Involvement of Vascular Prostaglandin Synthesis in the D irect Venous Vasoactivity of Furosemide
In vivo, an increase in the venous capacitance induced by systemically administered furosemide has been reported to be inhibitable by indomethacin.3 This observation suggests a role for prostaglandins as a mediator of vasoactive effects of furo sem ide. The source of the prostaglandins involved in this mechanism may be the kidneys, because they may release prostaglandins into the systemic circulation3; alternatively, local production in the peripheral vasculature could be in volved J K To determine the role of the nonrenal prostaglandins in the venous vasoactive effects of furosemide, we examined the effect of locally administered indomethacin (12.5 jag/min, 10 m inutes) on the furosemide-induced venous vasoactivity. In 8 subjects, furosemide (100 ¿¿g/min) together with a placebo (N aC l 0.9%, 0.1 mL/min) was locally infused into a precon stricted vein for 10 minutes. Venodilation was assessed, after which placebo was replaced by indomethacin for 10 minutes and venodilation was assessed again.
T o exclude a possible constrictor response by indomethacin alone, control experiments were performed in 4 subjects to determ ine the effect of indomethacin (12.5 and 125 /xg/min) on baseline venous tone.
Involvement of Vascular NO Synthesis in the Direct Venous Vasoactivity of Furosemide
N O is a potent vasodilator released by vascular endothelial cells. Although the furosemide-induced vascular effects in vitro appear to be independent of the endothelium,7 a recent study show ed that furosemide augmented the NO production of isolated cultured endothelial cells,1* To study the role of NO in the furosemide-induced venous vasoactivity, we repeated the protocol as described above, now using L-NMMA (60 pig/mi a) instead of indomethacin to inhibit NO production. Extensive studies have shown that this dose of L-NMMA has no effect on basal venous toneiy and is able to block the venodilation caused by acetylcholine.2"
Effect of Systemic Administration of Furosemide on D orsal Hand Vein Distensibility
All previous reports concerning the effects of furosemide on human vein capacitance used systemic administration. 10 To exam ine whether furosemide administered systemically in ther apeutic dosages exerts a vasodilator activity comparable to that o f locally administered furosemide, we administered furo sem ide (40 mg) intravenously in the contralateral arm in 15 subjects. Venous distensibility of the precontracted hand vein was recorded during the following 8 minutes.
Drugs
Furosemide solutions were freshly prepared from 2-mL ampoules containing 10 mg/mL furosemide as a disodium salt (Lasix, Hoechst Marion Roussel) and were further diluted in physiological saline immediately before each experiment. Nor epinephrine (1-mg/mL ampoules), indomethacin (Indocid F D A , Merck Sharp and Dohme, 1 mg/mL), and L-NMMA acetate (Clinalfa) were dissolved in physiological saline imme diately before use.
D a ta Analysis
Data are expressed as mean±SEM unless noted otherwise and were analyzed by Student's t test or repeated measures ANOVA for paired data if appropriate. If ANOVA showed that a significant difference existed between conditions, it was followed by post hoc / tests (including Bonferroni correction) to determine dose dependency or time dependency. Linear regression analysis was performed on the relation between age and percentage furosemide-induced venodilation (correlation coefficient according to Pearson). A value of P<.05 was considered to indicate significance.
Direct arterial vasoactivity. To reduce the variability of blood flow data and to correct for systemic changes, the ratio of the FBF measurements in the infused and noninfused arms was calculated for each time point, with the noninfused arm used as a contemporaneous control for the infused arm. 21 The FBF values of the last 3 minutes of each drug infusion were averaged to one value.
Direct venous vasoactivity. The response of norepinephrineinduced constriction was measured, and furosemide-induced effects were expressed as the percentage attenuation of the average control constriction. All results are expressed as a percentage of baseline vein size. The furosemide-induced venodilation was determined during the last 3 minutes of each furosemide infusion.
Results
Systemic Effects
Forearm volum e averaged 984±32 mL. During the arterial vasoactivity experiments, blood pressure, heart rate, and FBF in the noninfused arm did not change significantly after intrabrachial infusion of furosemide. During local administration o f furosemide in the venous vasoactivity experiments, blood pressure increased over ««I hour from 1 1 3 ± 2 /6 2 ± 1 to 116±2/66±2 mm Hg (for systolic and diastolic blood pressures, P =,03 and P -.0 0 1 , respectively, A N O V A with repeated measures). There was no change in heart rate (61 ± 2 to 61 ± 2 bpm, P = N S ).
M ore relevantly, blood pressure increased within 5 minutes after systemic administration of 40 mg of furo sem ide from 118± 1/68± 2 to 121±2/71±2 mm Hg (P = .01 and P c , 0001, respectively, Student's t test). Heart rate remained unchanged (63±2 to 65±1 bpm).
Direct Effects on FBF
Ratios o f infused to control FBF and ipsilateral venous plasma concentrations of furosemide are shown in Fig 1 (top) . During five increasing dosages of furo semide, there was no significant effect on FBF compared with the placebo infusion. In 6 subjects, we infused furosemide 1000 \xg * m in" 1 * dL"1 for 6 minutes, leading to local furosemide plasma concentrations of 234±40 /xg/mL. In these subjects, furosemide increased FBF in the infused arm slightly, by 23±9.7% (P<.05), but without a significant effect on the FBF ratio of the infused and noninfused arms (P=.08).
Intra-arterial bum etanide infusions led to local plasma concentrations ranging from 39±11 to 1748±327 ng/mL and also failed to alter FBF (data not shown).
Effect of furosemide on norepinephrine-induced vasocon striction. A s shown in Fig 1 (bottom) , local infusion of norepinephrine into the brachial artery led to a dosedependent decrease in FBF (7J<.001), with no significant effect on systemic blood pressure. This vasoconstriction was not inhibited by local infusion of furosemide (P = N S ). Fig 3 (right) shows that furo semide-induced venorelaxation was not inhibited by local L-NM M A administration. In this subgroup, veno relaxation was 60± 11% before and 53±14% after pla cebo was replaced by L -N M M A ( n = 8, P = N S ).
Direct Effects on Dorsal Hand Vein Distensibility
Effect o f systemic administration of furosemide on dorsal hand vein distensibility. A s shown in Fig 2 (right) , paren- does have a direct venodiiator effect, which is associated with vascular prostaglandin synthesis.
Direct Effects on FBF
Our results demonstrate the absence o f a direct effect o f loop-active diuretics on FBF during intra-arterial infusions, which results in clinically relevant plasma concentrations in the infused forearm. The absence of vasoactivity in this concentration range is consistent with most previous experiments on isolated arteries.7'9 In these in vitro experiments, direct vasodilator properties of furosemide were observed only at concentrations >10"4 mol/L, whereas in our first series of experiments, the furosemide concentration at the highest infusion rate reached 4 7 ± 1 0 ¿¿g/mL, equivalent to 1.4X 10'4 mol/L. To examine the direct arterial effects of furo semide at very high concentrations in vivo, w e infused furosemide 1000 ¡xg * min"1 * dL"1 into the brachial artery, leading to a local concentration o f 234± 40 ¿¿g/mL (0.71 X10"3 m ol/L). Even at these supratherapeutic concentrations, only a negligible increase in FBF was observed.
In the rat, furosemide did not change baseline m es enteric blood flow, but systemic administration did in hibit the decrease in blood flow produced by angiotensin II and norepinephrine.14 In contrast, we observed no effect of local furosemide on norepinephrine-induced attenuation of FBF. From our studies, we conclude that furosemide does not exert any direct arterial vasodilator or antivasoconstrictor activity in the human forearm. As such, the previously reported decrease in FBF after systemic administration of furosemide3-4'22 is probably due to an indirect effect of the drug, in particular a stimulation of the renin-angiotensin system.5 O f course, our experiments do not allow us to exclude direct arterial vasoactivity of furosemide in other vascular beds, eg, the lung or kidney.
Direct Effects on Dorsal Hand Vein Distensibility
The present investigation shows that furosemide exerts a direct vasodilator effect on preconstricted dorsal hand veins. Time-controi experiments demonstrated that this effect of furosemide cannot be explained by a spontaneous reduction in norepinephrine-induced constriction over time. The local concentration of furosemide cannot be estimated precisely because the venous flow was not mea sured in these studies. However, if the flow in the dorsal hand vein is assumed to be 1 mL/min (5% of arterial F),23 furosemide plasma concentrations can be esti mated to range from 0.2 to 20 jug/mL during our doseresponse studies. Systemic administration of 40 mg furo semide leads to a plasma concentration of 3.8 ± 0.3 jitg/mL in the first 15 minutes in normal subjects,24 which is within the range of the estimated plasma concentrations. This, as well as the observation of a similar venodiiator effect after systemic administration of 40 mg furosemide, suggests that the increase of venous compliance observed after systemic administration of furosemide may be the result of direct effects on the venous circulation. Compared with other substances such as nitroprusside25 and substance P,26 which exert venodilatory properties at an infusion rate of nano grams per minute, furosemide is much less potent. How ever, its effect does have clinical relevance, especially in the first few minutes after parenteral administration. 
Mechanism of Action
Conclusions
The present study provides the first evidence that furosemide at therapeutic concentrations exerts no di rect vasodilator or antivasoconstrictor effect on arterial resistance vessels in the human forearm but rather directly dilates veins in humans. The direct venodilation was inhibited by local indomethacin administration but not by blockade of N O synthesis, indicating that the direct vascular venodilation is dependent on local pros taglandin but not on N O production. Hemodynamic changes observed directly after systemic administration of furosemide are probably due to a direct venodiiator effect of the drug.
